Name | Dapoxetine hydrochloride |
Description | Dapoxetine hydrochloride (LY-210448 hydrochloride) is a selectivity short-acting serotonin reuptake inhibitor, used for the therapy of premature ejaculation. |
Kinase Assay | PKA enzyme activity: cAMP-dependent protein kinase activity is assayed in a reaction mixture containing, in a final volume of 0.2 mL, 50 mM Tris-HC1 (pH 7.0), 10 mM magnesium acetate, 2 mM EGTA, 1 μM cAMP or absence of cAMP, 3.3-20 μM [γ-32P]ATP (4 × 105 cpm), 0.5 μg of the enzyme, 100 μg of histone H2B, and each compound, as indicated. |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | H2O : 25.6 mg/mL (75 mM) DMSO : 50 mg/mL (146.25 mM)
|
Keywords | Benign | BPH | serotonin reuptake | SERT | sexual disorder | LY 210448 | LY-210448 Hydrochloride | SLC6A4 | LY210448 Hydrochloride | Dapoxetine hydrochloride | LY210448 | Dapoxetine | 5-HTT | inhibit | Inhibitor | LY 210448 Hydrochloride | Premature ejaculation | Serotonin Transporter | Prostate Hyperplasia | Dapoxetine Hydrochloride |
Inhibitors Related | Alverine citrate | CLOZAPINE N-OXIDE | Amitriptyline hydrochloride | Trazodone hydrochloride | Mianserin hydrochloride | Fluoxetine hydrochloride | Cinchonidine |
Related Compound Libraries | Bioactive Compound Library | Anti-Neurodegenerative Disease Compound Library | Pain-Related Compound Library | Membrane Protein-targeted Compound Library | EMA Approved Drug Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Drug Library |